SEC 13F Intelligence

Baker Bros. Advisors LP / RARE

Baker Bros. Advisors LP’s Ultragenyx Pharmaceutical In Position

Does Baker Bros. Advisors LP own Ultragenyx Pharmaceutical In (RARE)? Not currently — the last reported position was 2.77M shares worth $64M in Q4 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$64M
Q4 2025
Shares
2.77M
% of Portfolio
+0.37%
Quarters Held
21
position exited

Position History RARE

Reported value by quarter
Q4 ’20: $62MQ4 ’20Q1 ’21: $51MQ2 ’21: $42MQ3 ’21: $40MQ3 ’21Q4 ’21: $37MQ1 ’22: $32MQ2 ’22: $28MQ2 ’22Q3 ’22: $20MQ4 ’22: $22MQ1 ’23: $19MQ1 ’23Q2 ’23: $36MQ3 ’23: $49MQ4 ’23: $70MQ4 ’23Q1 ’24: $68MQ2 ’24: $60MQ3 ’24: $88MQ3 ’24Q4 ’24: $66MQ1 ’25: $57MQ2 ’25: $101MQ2 ’25Q3 ’25: $83MQ4 ’25: $64Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q4 20252.77M$64M+0.37%
Q3 20252.77M$83M+0.60%
Q2 20252.77M$101M+0.98%
Q1 20251.58M$57M+0.63%
Q4 20241.58M$66M+0.71%
Q3 20241.58M$88M+0.91%
Q2 20241.47M$60M+0.77%
Q1 20241.47M$68M+0.86%
Q4 20231.47M$70M+0.80%
Q3 20231.37M$49M+0.28%
Q2 2023783.1K$36M+0.21%
Q1 2023471.0K$19M+0.10%
Q4 2022471.0K$22M+0.13%
Q3 2022471.0K$20M+0.13%
Q2 2022471.0K$28M+0.16%
Q1 2022444.4K$32M+0.19%
Q4 2021444.4K$37M+0.18%
Q3 2021444.4K$40M+0.18%
Q2 2021444.4K$42M+0.19%
Q1 2021444.4K$51M+0.22%
Q4 2020444.4K$62M+0.23%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Baker Bros. Advisors LP’s full portfolio or all institutional holders of RARE.